Introduction
============

Muscle atrophy reflects a systemic response to various chronic conditions, including heart failure (HF) ([@b1-ijmm-41-05-2678],[@b2-ijmm-41-05-2678]). Disease-associated decreases in the size of muscle tissue can occur as a result of various pathologies and one such reported causative factors is hypoxia ([@b3-ijmm-41-05-2678]--[@b5-ijmm-41-05-2678]).

Exercise intolerance and skeletal muscle dysfunction are among the fundamental features of HF pathophysiology, and are associated with limited everyday function and poor patient outcomes ([@b6-ijmm-41-05-2678]--[@b8-ijmm-41-05-2678]). The mass and volume of skeletal muscle in different regions of the body are decreased in patients with HF ([@b9-ijmm-41-05-2678]--[@b12-ijmm-41-05-2678]), and skeletal muscles are more prone to exertion fatigue ([@b13-ijmm-41-05-2678],[@b14-ijmm-41-05-2678]). The skeletal muscle wasting known as cardiac cachexia ([@b15-ijmm-41-05-2678]) may also be observed in histopathological evaluations where fibre atrophy is observed ([@b16-ijmm-41-05-2678],[@b17-ijmm-41-05-2678]) and at the molecular level as the proteolysis by the ubiquitin-proteasome system is activated ([@b18-ijmm-41-05-2678]).

Iron deficiency is one of the potential pathomechanisms that contribute to muscle dysfunction in HF ([@b19-ijmm-41-05-2678]--[@b21-ijmm-41-05-2678]). The beneficial effects of iron supplementation on the improvement of muscle function in patients with HF have already been reported ([@b22-ijmm-41-05-2678],[@b23-ijmm-41-05-2678]); however, the associated mechanisms remain to be elucidated.

It may be hypothesized that the disturbed iron metabolism observed in HF affects skeletal muscles, which leads to their dysfunction and exercise intolerance. The present authors have recently demonstrated that, during hypoxia, reduced iron concentration had a greater negative impact on the viability and functioning of myocytes, compared with augmented iron availability ([@b24-ijmm-41-05-2678]).

As hypoxic conditions, which occur in the course of HF are difficult to be introduced and manipulated in humans and animals, a model of skeletal myocyte cultures was established in the present study. The aim of the present study was to investigate the influence of iron availability and hypoxia in the context of muscle atrophy markers and cell morphology in a rat skeletal myocyte cell line (L6G8C5).

The following parameters were measured in the L6 cell line using differing states of iron availability in the culture medium: *Atrogin-1* and muscle-specific RING-finger 1 (*MuRF-1*), which are muscle-specific ubiquitin E3-ligases that are a part of the ubiquitin proteasome pathway associated with protein degradation during muscle atrophy, and are markedly induced in almost all types of atrophy ([@b25-ijmm-41-05-2678]--[@b27-ijmm-41-05-2678]); mothers against decapentaplegic homolog 4 (*SMAD4*), which is a transcriptional factor that serves a central role in the balance between atrophy and hypertrophy ([@b28-ijmm-41-05-2678]--[@b30-ijmm-41-05-2678]); and *Desmin*, which is a structural protein that builds class-III intermediate filaments found in muscle cells. B cell lymphoma-2 (Bcl-2) associated protein X (Bax)/Bcl-2 gene expression ratio ([@b31-ijmm-41-05-2678]) and expression of transferrin receptor 1 (*TfR1*) ([@b32-ijmm-41-05-2678]) were evaluated as previously described ([@b24-ijmm-41-05-2678]), to evaluate apoptotic activity and iron influx, respectively.

Materials and methods
=====================

Experimental schedule
---------------------

Rat L6G8C5 skeletal myocytes (L6; Sigma-Aldrich; Merck KGaA, Darmstadt, Germany) were cultured in normoxia (18% O~2~, 5% CO~2~) or hypoxia (1% O~2~, 5% CO~2~, 94% N~2~), for 48 h ([@b24-ijmm-41-05-2678]), supplemented with 100 *µ*M deferoxamine (DFO; Sigma-Aldrich; Merck KGaA) or 200 *µ*M ammonium ferric citrate (AFC; Sigma-Aldrich; Merck KGaA) in order to change iron accessibility ([Fig. 1](#f1-ijmm-41-05-2678){ref-type="fig"}). Controls were grown in normal cell culture conditions in normoxia for 48 h. DFO is a selective iron chelator that is typically used in cell culture studies. It has been reported that the addition of DFO into culture medium reduces iron concentration both in the cellular environment and inside the cell, as DFO may be taken up via fluid phase endocytosis ([@b33-ijmm-41-05-2678]). AFC was previously applied in cell culture studies in order to induce intracellular iron uptake ([@b34-ijmm-41-05-2678],[@b35-ijmm-41-05-2678]). Compounds were added to cells from 1,000X concentrated stock, diluted in culture medium. Hypoxia was generated in a standard cell culture incubator by displacing O~2~ with infusion of N~2~, which was supplied by an external high-pressure liquid nitrogen tank.

Cell culture conditions
-----------------------

L6 cells were grown in 37°C in Dulbecco\'s modified Eagle\'s medium (DMEM; Sigma-Aldrich; Merck KGaA) with the addition of 10% fetal bovine serum (FBS; Invitrogen; Thermo Fisher Scientific, Inc., Waltham, MA, USA), 2 mmol/l glutamine, 1 U/ml penicillin and 10 mg/ml streptomycin (all from Sigma-Aldrich; Merck KGaA). For passages, cells were washed with PBS (without ions Ca^2+^ and Mg^2+^) and released via the use of Trypsin (Sigma-Aldrich; Merck KGaA). Cells were maintained according to manufacturer\'s guidelines.

Iron content in cells
---------------------

The measurement of intracellular iron content was performed via flame atomic absorption spectroscopy assay ([@b36-ijmm-41-05-2678]). Briefly, 2×10^6^ cells, cultured according to the aforementioned protocol, were dissociated by trypsinisation, pelleted by centrifugation (5 min; room temperature; 500 × g), and washed five times with PBS in order to remove free iron ions from the medium. The pellet was dissolved in 250 *µ*l radioimmunoprecipitation assay (RIPA) buffer (Sigma-Aldrich; Merck KGaA) for 30 min on ice and sonicated on ice (20 kHz; 10 sec) to disaggregate cellular structures. The protein concentration in the cell lysate was determined using the Lowry method ([@b37-ijmm-41-05-2678]). Intracellular iron content was measured in 250 *µ*l of medium containing 1 mg protein lysate using an atomic absorption spectrometer (SOLAAR M6; Thermo Elemental, Ltd., Cambridge, UK) equipped with a deuterium lamp for background radiation correction by direct calibration against aqueous standards. An air-acetylene flame was used (gas flow, 0.9 l/min). The calibration solutions were prepared following successive dilutions of the stock standard solution (iron standard for AAS TraceCERT; 1,000 ppm; Sigma-Aldrich; Merck KGaA). The final iron concentration in the successive dilutions of the stock solution varied from 0.5--2.0 ppm. All solutions were diluted to 1:5 with deionized water. Measurements were made under the following conditions: Burner, 100 mm; wavelength, λ=253.7 nm; background correction (quadline bandpass, 0.2 nm); lamp current, 75%. The method was verified by determination of reference material \[Seronorm™ Trace Elements Serum level I: Fe=1.39 mg/l; level II: Fe=1.91 mg/l (SERO AS, Billingstad, Norway)\].

Reverse transcription-quantitative polymerase chain reaction (RT-qPCR)
----------------------------------------------------------------------

Total RNA was isolated from L6 cells harvested from 6-well tissue culture plates (Sarstedt AG, Göttingen, Germany) using the RNeasy^®^ Fibrous Tissue Mini kit (Qiagen GmbH, Hilden, Germany) according to the manufacturer\'s instructions. The protocol included an on-column DNAse digestion to remove genomic DNA. First-strand cDNA was synthesized using a superscript™ III First-strand synthesis system with oligo(dT)~20~ primer according to the manufacturer\'s protocol (Invitrogen; Thermo Fisher Scientific, Inc.). The following primer sequences were used and designed with Molecular Beacon Software (Bio-Rad Laboratories, Inc., Hercules, CA, USA): *Atrogin-1* forward, 5′-AGCTTGTGCGATGTTACCCA-3′ and reverse, 5′-GAGCAGCTCTCTGGGTTGTT-3′; *MuRF1* forward, 5′-TGCAAGGAACACGAAGACGA-3′ and reverse, 5′-ACAAGGAGCAAGTAGGCACC-3′; *SMAD4* forward, 5′-CGGGTTGTCTCACCTGGAAT-3′ and reverse, 5′-TGGATGCGCGATTACTTGGT-3′; *Desmin* forward, 5′-GACCTTCTCTGCTCTCAACTTCC-3′ and reverse, 5′-CGCTGACGACCTCTCCATCC-3′; *Bcl-2* forward, 5′-AGCATGCGACCTCTGTTTGA-3′ and reverse, 5′-TCACTTGTGGCCCAGGTATG-3′; *Bax* forward, 5′-TGGCGATGAACGGACAACA-3′ and reverse, 5′-CACGGAAGAAGACCTCTCGG-3′; and *TfR1* forward, 5′-GAGACTACTTCCGTGCTACTTC-3′ and reverse, 5′-TGGAGATACATAGGGTGACAGG-3′. The primers spanned exon junctions to prevent the amplification of genomic DNA. The reference genes, *β-actin* (*actb*; *Rattus norvegicus*) and *18S ribosomal RNA* (rRNA; *18s*; *Rattus norvegicus*), were provided with a geNorm kit (ge-SY-12; PrimerDesign, Ltd., Southampton, UK) and used in all measurements. All experiments were performed in triplicate. The qPCR assay (consisting of an initial denaturation step at 95°C followed by 40 cycles of denaturation steps at 95°C for 10 sec and primer annealing/extension at 60°C for 15 sec) was performed using the CFX Connect™ Real-Time PCR Detection system and SsoFast™ EvaGreen^®^ Supermix reagent (both from Bio-Rad Laboratories, Inc.). The specificity of PCR was determined by melt-curve analysis for each reaction. The amplification efficiency was estimated by running serial dilutions of a template. Successive dilutions were plotted against the appropriate Cq values to generate a standard curve. The slope calculated from the standard curve was used to determine the amplification efficiency (E) according to the formula: E=10^−1^/slope. The amplification efficiencies for the target amplicons, *β-actin* and *18S rRNA* were not comparable and the Pfaffl method was used to determine the relative expression ([@b38-ijmm-41-05-2678]).

Western blotting
----------------

L6 cells were homogenised on ice in RIPA buffer \[10 mM Tris-Cl (pH 8.0), 1 mM EDTA, 0.5 mM EGTA, 1% Triton X-100, 0.1% sodium deoxycholate, 0.1% SDS, 140 mM NaCl, 1 mM PMSF\] for 60 min, followed by sonication on ice (20 kHz; 10 sec). Protein concentration was estimated by BCA assay ([@b39-ijmm-41-05-2678]). In order to determine *Atrogin-1*, *MuRF-1*, *SMAD4* and *desmin* protein levels, 30 *µ*g appropriate protein lysates (\~10 *µ*l) were separated by 12% SDS-PAGE. Proteins were electro-transferred on polyvinylidene fluoride membranes (EMD Millipore, Billerica, MA, USA) in Towbin buffer (25 mM Tris, 192 mM glycine) supplemented with 20% methanol. Membranes were blocked with 5% skimmed milk for 1 h at room temperature and incubated with primary antibodies ([Table I](#tI-ijmm-41-05-2678){ref-type="table"}) overnight at 4°C. Following washing (3×10 min; TBs, Tween-20), membranes were incubated with secondary horseradish peroxidase-conjugated anti-rabbit and anti-mouse antibodies ([Table I](#tI-ijmm-41-05-2678){ref-type="table"}) and developed with ECL or Femto detection systems (Pierce; Thermo Fisher Scientific, Inc.). The data was obtained from three separate experiments.

Immunofluorescence and imaging
------------------------------

For immunofluorescence, cells were grown to 70--90% confluency on sterile coverslips placed in 6-well plates (Sarstedt AG). Cells were fixed in 4% formalin in PBS for 20 min at room temperature, then unmasked in Target Retrieval Solution (pH 9; Dako; Agilent Technologies, Inc., Santa Clara, CA, USA) in 95°C for 10 min, permeabilized with 0.1% Triton X-100 in PBS (3×7 min), washed with PBS and blocked at room temperature for 1 h with PBS containing 10% FBS. Double-immunofluorescence staining was applied as cells were incubated overnight at 4°C with primary antibodies ([Table I](#tI-ijmm-41-05-2678){ref-type="table"}), washed with PBS and subsequently incubated for 2 h at room temperature with fluorescein isothiocyanatae- or rhodamine-conjugated secondary antibodies ([Table I](#tI-ijmm-41-05-2678){ref-type="table"}) and DAPI (2 *µ*g/ml; Santa Cruz Biotechnology, Inc., Dallas, TX, USA) as a nuclei marker. Control reactions were performed without primary antibodies. Labelled cells were mounted in ProLong Gold Antifade Mountant (Thermo Fisher Scientific, Inc.). Cells were viewed using a Nikon Eclipse 80i fluorescence microscope (Nikon Corp., Tokyo, Japan) with 40× objective lens. Representative images were chosen from each sample and were processed with the use of ImageJ 1.51 h (National Institutes of Health, Bethesda, MD, USA). Data was obtained from three separate experiments.

Statistical analysis
--------------------

Data are presented as the mean ± standard deviation unless otherwise indicated. Kruskall-Wallis analysis followed by post-hoc Dunn\'s multiple comparison test was used to compare the groups. All experiments were performed in triplicate. Spearman\'s rank correlation coefficient was calculated between the expression of *Atrogin-1, MuRF-1, SMAD4* and *Desmin* genes in three states of iron concentrations or between expression of the aforementioned genes and *Bax/Bcl2* or *TfR1* in those same conditions. P\<0.05 was considered to indicate a statistically significant difference.

Results
=======

Changes in intracellular iron due to the addition of DFO or AFC to culture media
--------------------------------------------------------------------------------

The mean intracellular content of iron in L6 cells in the standard DMEM medium was 0.91 mg/l. The direct measurement of intracellular iron demonstrated that the addition of 100 *µ*M DFO to the medium caused a decrease of intracellular iron concentration to 0.41 mg/l. In contrast, a supplementation of medium with 200 *µ*M AFC increased mean intracellular iron concentration to 5.12 mg/l (data not shown).

Effects of differing iron availability during normoxia or hypoxia on the morphology of skeletal myocytes
--------------------------------------------------------------------------------------------------------

The exposition of skeletal myocytes to hypoxia alone did not markedly affect the morphology of the studied cell line. Notably, the morphological abnormalities within skeletal myocytes, such as cell shrinkage and pyknosis, occurred upon decreased iron availability in both normoxic and hypoxic conditions. In turn, AFC treatment upon both optimal and reduced oxygen concentration did not lead to any marked alterations in cellular morphology ([Fig. 2](#f2-ijmm-41-05-2678){ref-type="fig"}).

Effects of differing iron availability on the atrophy markers Atrogin-1 and MuRF1 in skeletal myocytes
------------------------------------------------------------------------------------------------------

The effect of iron availability on levels of *Atrogin-1* and *MuRF1* were assessed ([Fig. 3](#f3-ijmm-41-05-2678){ref-type="fig"}). Hypoxic treatment of L6 skeletal myocytes caused, as compared with the untreated cells, a significant increase in mRNA expression of *Atrogin-1* (P\<0.001; [Fig. 3A](#f3-ijmm-41-05-2678){ref-type="fig"}). L6 cells when exposed to iron-deficient environment demonstrated, as compared with the cells cultured in optimal iron concentration, significantly increased mRNA expression of *Atrogin-1* in both normoxia (P\<0.01) and hypoxia (P\<0.05; [Fig. 3A](#f3-ijmm-41-05-2678){ref-type="fig"}), indicating enhanced protein degradation in the cells. Notably, the increase in *Atrogin-1* mRNA expression was greater during hypoxia and concomitant reduced iron availability than in hypoxia alone (P\<0.05). In turn, AFC treatment of myocytes did not significantly affect the mRNA expression of *Atrogin-1* under optimal oxygen levels, whereas during hypoxia the expression of the aforementioned marker was significantly decreased, as compared with cells cultured in optimal (P\<0.05) and reduced iron concentrations (P\<0.001; [Fig. 3A](#f3-ijmm-41-05-2678){ref-type="fig"}). Western blot analysis and immunocytochemical staining revealed similar patterns of changes at the protein level ([Fig. 3C and D](#f3-ijmm-41-05-2678){ref-type="fig"}).

Low oxygen concentration did not significantly affect the mRNA expression of *MuRF1* ([Fig. 3B](#f3-ijmm-41-05-2678){ref-type="fig"}), as compared with untreated cells. The exposure to DFO induced a significant increase in mRNA expression of *MuRF1* in normoxia (P\<0.05) and hypoxia (P\<0.05), as compared with cells cultured in optimal iron concentration. Notably, skeletal myocytes demonstrated a greater increase in mRNA expression of *MuRF1* when cultured in low iron availability during hypoxia than in normoxic conditions. In turn, increased iron availability induced a significant decrease in mRNA expression of *MuRF1* during normoxia (P\<0.05) and hypoxia (P\<0.001), compared with optimal iron levels. Western blot analysis and immunocytochemical staining revealed similar patterns of changes at the protein level ([Fig. 3C and E](#f3-ijmm-41-05-2678){ref-type="fig"}). Notably, the mRNA expression of *MuRF1* during hypoxia was significantly associated with mRNA expression of *Atrogin-1* (R=0.98, P\<0.001) regardless of iron status. Further, in hypoxia an increased expression of *Atrogin-1* and *MuRF1* was associated with an increased expression of *Tfr1* ([@b24-ijmm-41-05-2678]), reflecting intracellular iron demand (R=0.91, P\<0.01; R=0.86, P\<0.01; data not shown). The aforementioned associations were not observed under normoxic conditions.

Effects of differing iron availability on the expression of SMAD4 in skeletal myocytes
--------------------------------------------------------------------------------------

The exposure of skeletal myocytes to hypoxia alone did not significantly affect the mRNA expression of *SMAD4*. In turn, reduction of iron availability resulted, as compared with the cells cultured in optimal iron concentrations, in significantly decreased mRNA expression of *SMAD4* under hypoxia (P\<0.001), suggesting a shift towards atrophy in the atrophy-hypertrophy balance; whereas during normoxia, the expression of this transcription factor was not significantly changed ([Fig. 4A](#f4-ijmm-41-05-2678){ref-type="fig"}). When exposed to iron supplementation with AFC in normoxic conditions, L6 cells exhibited a significant increase in mRNA expression of *SMAD4* compared with cells cultured in optimal iron concentration (P\<0.001). Western blot analysis and immunocytochemical staining confirmed that hypoxia treatment did not alter the protein expression of *SMAD4* ([Fig. 4B and C](#f4-ijmm-41-05-2678){ref-type="fig"}). In turn, the addition of DFO or AFC to the culture medium caused, a marked decrease or increase, respectively, in the protein level of *SMAD4* during hypoxia and normoxia, compared with the cells cultured in optimal iron concentrations ([Fig. 4B and C](#f4-ijmm-41-05-2678){ref-type="fig"}). Notably, the mRNA expression of *SMAD4* during hypoxia and concomitant different iron status was significantly associated with mRNA expression of *Tfr*1 ([@b24-ijmm-41-05-2678]) (R=−0.94, P\<0.01) and apoptotic activity measured as Bax/Bcl-2 ([@b24-ijmm-41-05-2678]) gene expression ratio (R=−0.79, P\<0.05) (data not shown). The aforementioned associations were not present upon normoxic conditions.

Effects of different iron availability on the expression of desmin in skeletal myocytes
---------------------------------------------------------------------------------------

Reduced iron availability resulted in significantly increased mRNA expression of *desmin* during normoxia and hypoxia, compared with the cells cultured in optimal iron concentrations (both, P\<0.001). Notably, the increase of *desmin* mRNA expression was markedly greater in low iron conditions during hypoxia than in reduced iron levels in normoxic conditions. Similarly, when exposed to AFC treatment, L6 skeletal myocytes exhibited a significant increase in the mRNA expression of *desmin* during normoxia and hypoxia, compared with the cells cultured in optimal iron concentrations (both, P\<0.05). The increase of mRNA expression of *desmin* was greater during hypoxia upon low iron treatment than in AFC-treated cells in normoxia. Western blot analysis ([Fig. 5B](#f5-ijmm-41-05-2678){ref-type="fig"}) and immunocytochemical staining ([Fig. 5C](#f5-ijmm-41-05-2678){ref-type="fig"}) revealed a similar pattern of changes at the protein level. Notably, the expression of *desmin* was significantly associated with increased mRNA expression of *TfR1* ([@b24-ijmm-41-05-2678]) during both normoxia and hypoxia, regardless of iron level (R=0.71, P\<0.05; R=0.79, P\<0.05). Furthermore, the expression of *desmin* during hypoxia with concomitant different iron status was significantly associated with apoptotic activity measured as the *Bax*/*Bcl-2* ([@b24-ijmm-41-05-2678]) gene expression ratio (R=0.93, P\<0.001) and with the decreased mRNA expression of *SMAD4* (R=−0.80, P\<0.01) (data not shown).

Discussion
==========

The present study provides an insight into the response of muscle-specific atrophy markers to increased or reduced iron availability in skeletal myocytes when cultured under normoxic or hypoxic conditions. In particular, it was demonstrated that iron depletion, when combined with hypoxia, induced abnormal cell morphology and an upregulation of key enzymatic components of intracellular regulatory system of muscle atrophy, namely muscle-specific ubiquitin E3-ligases *Atrogin-1* and *MuRF1*. Notably, it was demonstrated that augmented iron availability in hypoxic conditions acted in a protective manner in the context of these atrophy markers.

Skeletal muscle wasting has been insufficiently investigated in the context of iron metabolism. To date, there have been few studies that linked iron overload to muscle atrophy. For example, Ikeda *et al* ([@b40-ijmm-41-05-2678]) recently demonstrated that excess iron caused a decrease in mean size and muscle fibre area as well as an induction of *Atrogin-1* and *MuRF1* expression in mice subjected to 7- or 14-day iron injection treatment. However, it should be emphasized that animals that underwent the aforementioned experiment were healthy and, apart from iron load, no other factors mimicking any pathology were investigated in this study. Similarly, Reardon and Allen ([@b41-ijmm-41-05-2678]) previously demonstrated an iron-induced atrophy observed in murine skeletal muscle, but the process occurred only in soleus muscles and was not detected within the rest of the investigated muscles. There is also a scarcity of data on the influence of both iron excess and iron deficiency on atrophy markers in skeletal myocytes when exposed to hypoxia. The present authors previously studied the influence of increased or reduced iron availability in hypoxic conditions on skeletal myocytes and demonstrated that, during hypoxia, the reduced iron concentration had a more negative impact on the viability and apoptotic activity of the studied cells as compared with elevated iron availability ([@b24-ijmm-41-05-2678],[@b42-ijmm-41-05-2678]). The present authors\' preliminary results also demonstrated that, in skeletal myocytes, the mRNA expression of muscle-specific atrophy marker *Atrogin-1* was increased upon reduced iron availability, and was downregulated in increased iron concentrations ([@b24-ijmm-41-05-2678]).

In the present study, it was demonstrated that skeletal myocytes exposed to an iron-deficient environment demonstrated an upregulation of *Atrogin-1* and *MuRF1* at the mRNA and protein levels in hypoxia and normoxia, which suggested that catabolic activation and resulting protein degradation had occurred in the cells. The most severe impact in the context of muscle atrophy markers was observed in the combined conditions of hypoxia and iron deficiency. Notably, AFC-treated cells demonstrated an opposing trend, which suggested a protective influence of iron supplementation. This may support a molecular substantiation of efficacy of iron therapy for the improvement of muscle functional capacity in iron-deficient patients with HF ([@b22-ijmm-41-05-2678],[@b23-ijmm-41-05-2678]). Notably, the observed upregulation of both *Atrogin-1* and *MuRF1* in low-iron availability introduced in hypoxia was associated with increased expression of *Tfr1*, reflecting the association between an increased intracellular iron demand and catabolic activation of skeletal myocytes.

As the morphology of cells cultured in and iron-deficient environment was altered both in normoxia and hypoxia as compared with optimal or augmented iron availability, the expression of *desmin*, a muscle-specific cytoskeletal intermediate filament, was investigated ([@b43-ijmm-41-05-2678],[@b44-ijmm-41-05-2678]). To the best of our knowledge, *desmin* has not previously been analysed in skeletal muscle in the context of iron availability. In the present study, it was demonstrated that reduced and increased iron concentration lead to the upregulation of *desmin*, whereas hypoxia strengthened this effect. The aforementioned alterations may be considered as a maladaptive mechanism resulting in abnormal *desmin* accumulation, which has recently been correlated with altered myofiber morphology or mitochondrial dysfunction ([@b45-ijmm-41-05-2678]). In another previous study, an increased expression of *desmin* in aging rat muscles was potentially linked to the altered contractile force ([@b46-ijmm-41-05-2678]). In the present study, it was demonstrated that both iron overload and iron depletion were associated with desmin accumulation, which was analogous to the association previously reported by Walter *et al* ([@b47-ijmm-41-05-2678]) who demonstrated the detrimental effect of both iron overload and iron deficiency on the function of liver mitochondria. However, it is notable that the greatest augmentation of *desmin* expression was observed in DFO-treated cells cultured in hypoxia, which suggests that these combined conditions have the most negative impact on the cell structure.

The influence of differing iron availability on skeletal myocytes cultured in hypoxic conditions has been poorly investigated also in the context of atrophy-hypertrophy balance thus far, therefore the expression of *SMAD4* was investigated, which is associated with equilibrium between novel protein accumulation and the degradation of existing proteins ([@b28-ijmm-41-05-2678],[@b29-ijmm-41-05-2678]). Notably, Sartori *et al* ([@b30-ijmm-41-05-2678]) previously revealed the occurrence of atrophy changes in the skeletal muscle of *SMAD4*-deficient mice. In the present study, it was discovered that, under hypoxia, reduced iron availability induced a decrease in *SMAD4* expression. This finding indicated that environmental iron limitation along with reduced oxygen may contribute to muscle atrophy. It was also demonstrated that, in hypoxic conditions, the increased iron concentration may be protective as it induced an increase in *SMAD4* expression, and therefore, a potential shift towards hypertrophy.

Together, the present data suggested that the combined conditions of hypoxia and iron deficiency are the most detrimental for skeletal myocytes in the context of morphology alterations and expression of atrophy markers. Conversely, it appears that elevated iron availability in hypoxic conditions may be beneficial to a certain extent for skeletal myocytes, preventing their catabolic activation. Although it is necessary to verify these results in more advanced experimental models, they still may provide a valuable starting point for the understanding of efficacy of iron therapy for the improvement of muscle functional capacity and exercise tolerance observed in patients with HF and concomitant iron deficiency.

Furthermore, it may be interesting to further investigate the level of atrophy markers in human skeletal muscle tissue samples obtained from iron-deficient patients with HF prior to and following receiving intravenous iron supplementation.
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![Different oxygen availability conditions (normoxia and hypoxia) with L6G8C5 myocytes cell culture and iron concentration manipulations. The following conditions are presented: (A) Reduced iron concentration (iron chelation using 100 *µ*M DFO); (B) optimal iron concentration (standard iron concentration in Dulbecco\'s modified Eagle\'s medium with 10% fetal bovine serum); and (C) increased iron concentration (iron supplementation with 200 *µ*M AFC). DFO, deferroxamine; AFC, ammonium ferric citrate.](IJMM-41-05-2678-g00){#f1-ijmm-41-05-2678}

![Bright field inverted microscope images of L6G8C5 cells in different iron availability conditions in normoxia and hypoxia. Scalebar length, 200 *µ*m. DFO, reduced iron concentration via deferroxamine; C, control; AFC, increased iron concentration via ammonium ferric citrate.](IJMM-41-05-2678-g01){#f2-ijmm-41-05-2678}

![Expression of atrophy markers in L6G8C5 cells with concomitant optimal, reduced or increased iron availability in normoxia and hypoxia. mRNA expression levels of (A) *atrogin-1* and (B) *MuRF1* in L6G8C5 cells. (C) Western blot analysis of respective proteins expression in the cell lysates. Representative images of immunocytochemical staining of (D) atrogin-1 and (E) MuRF1 in L6G8C5 cell lines (with DAPI as a nuclei maker). Scalebar length, 25 *µ*m. Data are presented as the mean + standard deviation obtained from three separate experiments. ^\*^P\<0.05; ^\*\*^P\<0.01; ^\*\*\*^P\<0.001. AU, arbitrary units; MuRF1, muscle-specific RING-finger 1; DFO, reduced iron concentration via deferroxamine; C, control; AFC, increased iron concentration via ammonium ferric citrate.](IJMM-41-05-2678-g02){#f3-ijmm-41-05-2678}

![Expression of *SMAD4* in L6G8C5 cells with concomitant optimal, reduced or increased iron availability in normoxia and hypoxia. (A) mRNA expression levels of *SMAD4* in L6G8C5 cells. (B) Western blot analysis of respective proteins expression in the cell lysates. (C) Representative images of immunocytochemical staining of *SMAD4* and DAPI as a nuclei marker in L6G8C5 cell lines. Scalebar length, 25 *µ*m. Data are presented as the mean + standard deviation obtained from three separate experiments. ^\*\*^P\<0.01; ^\*\*\*^P\<0.001. AU, arbitrary units; DFO, reduced iron concentration via deferroxamine; C, control; AFC, increased iron concentration via ammonium ferric citrate; SMAD4, mothers against decapentaplegic homolog 4.](IJMM-41-05-2678-g03){#f4-ijmm-41-05-2678}

![Expression of *Desmin* in L6 cells with concomitant optimal, reduced or increased iron availability in normoxia and hypoxia. (A) mRNA expression levels of *Desmin* in L6G8C5 cells. (B) Western blot analysis of respective proteins expression in the cell lysates. (C) Representative images of immunocytochemical staining of *Desmin* with DAPI as a nuclei marker in L6G8C5 cell lines. Scalebar length, 25 *µ*m. ^\*^P\<0.05; ^\*\*\*^P\<0.001. AU, arbitrary units; DFO, reduced iron concentration via deferroxamine; C, control; AFC, increased iron concentration via ammonium ferric citrate.](IJMM-41-05-2678-g04){#f5-ijmm-41-05-2678}

###### 

Antibodies and dilutions used for WB and IF.

  Antigen          Application (dilution)   Manufacturer                                Cat. no.
  ---------------- ------------------------ ------------------------------------------- -------------
  Atrogin-1        WB (1:200), IF (1:100)   Santa Cruz Biotechnology, Inc.              sc-166806
  MuRF1            WB (1:200), IF (1:100)   Santa Cruz Biotechnology, Inc.              sc-32920
  SMAD4            WB (1:200), IF (1:50)    Santa Cruz Biotechnology, Inc.              sc-7966
  Desmin           WB (1:200), IF (1:100)   Santa Cruz Biotechnology, Inc.              sc-14026
  Actin HRP        WB (1:5,000)             Santa Cruz Biotechnology, Inc.              sc-1616 HRP
  Rabbit IgG HRP   WB (1:15,000)            Jackson ImmunoResearch Laboratories, Inc.   111-035-045
  Mouse IgG HRP    WB (1:15,000)            Sigma-Aldrich; Merck KGaA                   A 9917
  Rabbit IgG R     IF (1:500)               Santa Cruz Biotechnology, Inc.              sc-2091
  Mouse IgG FITC   IF (1:500)               Santa Cruz Biotechnology, Inc.              sc-2010

Company locations are as follows: Santa Cruz Biotechnology, Inc. (Dallas, TX, USA); Jackson ImmunoResearch Laboratories, Inc. (West Grove, PA, USA); Sigma-Aldrich (Merck KGaA; Darmstadt, Germany). WB, western blotting; IF, immunofluorescence; MuRF1, muscle-specific RING-finger 1; SMAD4, mothers against decapentaplegic homolog 4; IgG, immunoglobulin G; HRP, horseradish peroxidase; R, rhodamine; FITC, fluorescein isothiocyanate.
